Taiwan - Delayed Quote TWD

PharmaEssentia Corporation (6446.TW)

1,190.00 -50.00 (-4.03%)

At close: October 30 at 1:30:13 PM GMT+8

Chart Range Bar

Loading chart for 6446.TW

Previous Close 1,240.00
Open 1,220.00
Bid 1,195.00 x --
Ask 1,200.00 x --
Day's Range 1,155.00 - 1,225.00
52 Week Range 407.92 - 1,645.00
Volume 3,422,488
Avg. Volume 3,132,871
Market Cap (intraday) 492.321B
Beta (5Y Monthly) 0.65
PE Ratio (TTM) 71.39
EPS (TTM) 16.67
Earnings Date (est.) --
Forward Dividend & Yield 1.49 (0.12%)
Ex-Dividend Date Jul 9, 2026
1y Target Est 1,437.27

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

www.pharmaessentia.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6446.TW

181.16%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

56.10%

1-Year Return

6446.TW

168.59%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

59.83%

3-Year Return

6446.TW

347.38%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

179.95%

5-Year Return

6446.TW

1,431.10%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

166.15%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY26

Revenue 5.12B

Earnings 2.15B

Profit Margin 41.97%

FY25

FY26

25.0%

30.0%

35.0%

40.0%

Analyst Price Targets

500.33 Low

1,437.27 Average

1,190.00 Current

2,143.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

36.76%
Return on Assets (ttm)

12.95%
Return on Equity (ttm)

23.34%
Revenue (ttm)

20.75B
Net Income Avi to Common (ttm)

7.63B
Diluted EPS (ttm)

16.67

Balance Sheet and Cash Flow

Total Cash (mrq)

24.47B
Total Debt/Equity (mrq)

2.78%
Levered Free Cash Flow (ttm)

2.68B

3017.TW

3443.TW

2383.TW

6472.TW

6669.TW

U.S. markets closed

PharmaEssentia Corporation (6446.TW)

2.59%

-2.06%

99.70%

180.86%

168.30%

1,426.15%

619.98%

PharmaEssentia Corporation Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch